Following the 90-percent year-to-date appreciation in Intercept Pharmaceutical, Inc. ICPT shares, RBC Capital Markets considers the stock's risk-reward to be balanced. RBC Capital Markets analyst Brian Abrahams downgraded Intercept from Outperform to Sector Perform with a $115 price target. SourceSeems like downside will take some place due to stochastics head south. $ICPT, Intercept Pharmaceuticals, Inc. / D